Fourth Quarter & Full Year 2022 Financial & Business Update

2022 and Recent Accomplishments Lay the Foundation for Continued Progress Commercial Products Pipeline Assets ✓ EU MAA approval Initiated monotherapy study PADCEV ✓ ✓ EV-103 Cohort K data and regulatory submission Completed EV-302 enrollment DV ✓ Initial EV-103 Cohort H neoadjuvant MIBC data LV Ongoing EU country launches ✓ MOUNTAINEER data in CRC SGN-B6A Initiated combination study with Keytruda Evaluating potential frontline combination approaches with KEYTRUDA ✓ Reported initial Phase 1 data TUKYSA ✓ Completed HER2CLIMB-02 enrollment for 1L/2L mBC1 ✓ Treated first patient in HER2CLIMB-05 1L trial SGN-PDL1V ✓ Initiated phase 1 study SGN-B7H4V ✓ Initiated phase 1 study ADCETRIS ✓ ECHELON-1 longer-term OS data in 1L HL ✓ FDA approval of pediatric indication in 1L HL ✓ innova TV-205 combination data SGN-ALPV ✓ Initiated phase 1 study TIVDAK ✓ Initial innovaTV-207 basket study data SGN-BB228 ✓ Initiated phase 1 study Seagen 1 HER2CLIMB-02 extension study enrollment continues in China 6

View entire presentation